EMA and FDA decisions based on flawed evidence to approve new cancer drugs negatively affect Latin American patients

Carlos E. Durán^*, Martín Cañás, Thierry Chistiaens

^*Corresponding author for this work

Research output: Contribution to journal › Letter › Academic › peer-review

5 Citations (Scopus)

Access to Document

@article{7e34b54bd6d544a299418a579e00cf7a,

title = "EMA and FDA decisions based on flawed evidence to approve new cancer drugs negatively affect Latin American patients",

author = "Dur{\'a}n, \{Carlos E.\} and Mart{\'i}n Ca{\~n}{\'a}s and Thierry Chistiaens",

year = "2019",

month = oct,

day = "15",

doi = "10.1136/bmj.l6017",

language = "English",

volume = "367",

journal = "The BMJ",

issn = "0959-8146",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - EMA and FDA decisions based on flawed evidence to approve new cancer drugs negatively affect Latin American patients

AU - Durán, Carlos E.

AU - Cañás, Martín

AU - Chistiaens, Thierry

PY - 2019/10/15

Y1 - 2019/10/15

UR - https://www.scopus.com/pages/publications/85073473191

U2 - 10.1136/bmj.l6017

DO - 10.1136/bmj.l6017

M3 - Letter

C2 - 31615783

AN - SCOPUS:85073473191

SN - 0959-8146

VL - 367

JO - The BMJ

JF - The BMJ

M1 - l6017

ER -